Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Enrolling by invitation · Phase 3 · NCT06859099
Conditions: Polyneuropathy, Inflammatory Demyelinating, Chronic
At a glance
- Research payments reported, 2025
- $45,420
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 300
About the trial
- Sponsor
- Sanofi
- Tested
- Riliprubart Prefilled Pen (PFP) (drug)
- Dates
- Started 2025-04-01; completion 2029-10-03
- Results posted
- Not yet
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300 participants will be enrolled to continue receiving treatment with riliprubart. The duration of participation for each participant will be up to approximately 4 years, including posttreatment follow-up. The treatment duration will be up to approximately 3 years. A participant who discontinues ri…
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $45,420 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Kansas Medical Center Research Inst Inc $26,750
- Alabama Neurology Associates PC $18,670
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.